PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Academy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, China.\', \'Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA.\', \'Department of Pediatrics, University of Iowa, Iowa City, IA, USA.\', \'Department of Pathology, New York Medical College, Valhalla, NY, USA.\', \'Fuzionaire, Inc., The Woodlands, TX, USA.\', \'General Nutraceutical Technology, Elmsford, NY, USA.\', \'Department of Otolaryngology, School of Medicine, New York Medical College, Valhalla, NY, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1096/fj.202001792R
?:doi
?:hasPublicationType
?:journal
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
is ?:pmid of
?:pmid
?:pmid
  • 33749932
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33749932>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33749932>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all